CN116918972A - 一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 - Google Patents
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116918972A CN116918972A CN202310770263.XA CN202310770263A CN116918972A CN 116918972 A CN116918972 A CN 116918972A CN 202310770263 A CN202310770263 A CN 202310770263A CN 116918972 A CN116918972 A CN 116918972A
- Authority
- CN
- China
- Prior art keywords
- glucan
- parts
- beta
- composition
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 84
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 241000233866 Fungi Species 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 230000008685 targeting Effects 0.000 title claims abstract description 18
- 150000002632 lipids Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 title abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 239000013078 crystal Substances 0.000 claims abstract description 15
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000222336 Ganoderma Species 0.000 claims abstract description 9
- 240000008397 Ganoderma lucidum Species 0.000 claims description 16
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 241000890685 Dictyophora rubrovolvata Species 0.000 claims description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- 239000004386 Erythritol Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 229940009714 erythritol Drugs 0.000 claims description 5
- 235000019414 erythritol Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 34
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 14
- 150000004676 glycans Chemical class 0.000 abstract description 4
- 229920001282 polysaccharide Polymers 0.000 abstract description 4
- 239000005017 polysaccharide Substances 0.000 abstract description 4
- 230000005856 abnormality Effects 0.000 abstract description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241001122767 Theaceae Species 0.000 abstract 1
- 241001313734 Dictyophora Species 0.000 description 48
- 239000000047 product Substances 0.000 description 21
- 241000700159 Rattus Species 0.000 description 14
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 206010067125 Liver injury Diseases 0.000 description 11
- 231100000753 hepatic injury Toxicity 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000001476 alcoholic effect Effects 0.000 description 10
- 239000007857 degradation product Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HSSYVKMJJLDTKZ-UHFFFAOYSA-N 3-phenylphthalic acid Chemical group OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1C(O)=O HSSYVKMJJLDTKZ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 235000020339 pu-erh tea Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UUNIOFWUJYBVGQ-UHFFFAOYSA-N 2-amino-4-(3,4-dimethoxyphenyl)-10-fluoro-4,5,6,7-tetrahydrobenzo[1,2]cyclohepta[6,7-d]pyran-3-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1C(C#N)=C(N)OC2=C1CCCC1=CC=C(F)C=C12 UUNIOFWUJYBVGQ-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 101100338512 Homo sapiens HDAC9 gene Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005640 poly alpha-1,3-glucan Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供了一种食用菌β‑葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用,属于食用菌提取多糖健康食品技术领域。本发明所述组合物包括食用菌β‑葡聚糖4~6份、桑多安1~2份、醣净5~7份、普洱茶晶1~2份、灵芝产品3~5份。本发明所述组合物可在临床中靶向性改善总胆固醇、甘油三酯和低密度脂蛋白异常,且组方原料获取容易,可长期服用,无毒副作用。
Description
技术领域
本发明属于食用菌提取多糖健康食品技术领域,尤其涉及一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用。
背景技术
β-葡聚糖是粮谷类作物和微生物细胞壁中富含的一种功能性多糖。现代医学和营养学的研究表明它具有调节机体免疫、抗癌、抗肿瘤、降低胆固醇、调节血脂和血糖等多种功能;在营养学中是一种营养成分抑制剂。目前β-葡聚糖主要是从酵母、燕麦和大麦中提取。近日成为新食品原料的β-1,3/α-1,3-葡聚糖是由7个β-1,3-D-葡萄糖和2个α-1,3-葡萄糖相互连接而成的9个D-葡萄糖为重复单元构成的直链多糖,是一种β-1,3键占比达75%以上的水溶性β-葡聚糖。但这些β-葡聚糖并不能从营养上针对总胆固醇、甘油三酯、低密度脂蛋白胆固醇等血脂异常人群靶向辅助降血脂调理需求进行相应调整。因此,针对血脂异常人群进行靶向调理血脂异常的功能配方还有待开发。
发明内容
有鉴于此,本发明的目的在于提供一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,能够有效改善总胆固醇、甘油三酯、低密度脂蛋白胆固醇异常。
为了实现上述发明目的,本发明提供了以下技术方案:
本发明提供了一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,按质量份数计,所述组合物包括:食用菌β-葡聚糖4~6份、桑多安1~2份、醣净5~7份、普洱茶晶1~2份、灵芝产品3~5份。
优选的,按质量份数计,所述组合物包括:食用菌β-葡聚糖5份、桑多安1.5份、醣净6份、普洱茶晶1.5份、灵芝产品4份。
优选的,所述食用菌β-葡聚糖来源于红托竹荪。
优选的,所述红托竹荪β-葡聚糖Smith降解产物中含有甘油、赤藓醇、阿拉伯糖、甘露糖、葡萄糖。
优选的,所述红托竹荪β-葡聚糖中含有1-3糖苷键、1-2,3糖苷键、1-3,4糖苷键、1-3,6糖苷键和/或1-2,3,4糖苷键。
优选的,所述灵芝产品选自灵芝孢子油或灵芝孢子粉。
本发明还提供了上述组合物的制备方法,包括如下步骤:将各原料按所述配比依次混合得到混合物。
本发明还提供了上述组合物在制备调理血脂异常产品中的应用。
优选的,所述产品包括食品、保健品或药品。
本发明的有益效果:
本发明所述组合物可在临床中靶向性改善总胆固醇、甘油三酯和低密度脂蛋白异常,且组方原料获取容易,可长期服用,无毒副作用。
附图说明
图1:红托竹荪β-葡聚糖Smith降解产物的GC色谱图;
图2:红托竹荪β-葡聚糖和新食品原料β-1,3-葡聚糖高碘酸氧化消耗曲线;
图3:红托竹荪β-葡聚糖的1H NMR和13C NMR谱图;
图4:新食品原料β-1,3-葡聚糖的1H NMR和13C NMR谱图;
图5:红托竹荪β-葡聚糖和新食品原料β-1,3-葡聚糖刚果红试验结果图;
图6:红托竹荪β-葡聚糖对酒精性肝损伤大鼠血清AST、ALT、TG的影响;
图7:红托竹荪β-葡聚糖对酒精性肝损伤大鼠肝脏SOD、GSH、MDA的影响;
图8:红托竹荪β-葡聚糖对酒精性肝损伤大鼠肝脏TNF-α和IL-6的影响;
图9:酒精性肝损伤大鼠的肝脏组织形态学观察(400×)。
具体实施方式
本发明提供了一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,按质量份数计,所述组合物包括:食用菌β-葡聚糖4~6份、桑多安1~2份、醣净5~7份、普洱茶晶1~2份、灵芝产品3~5份。优选的,所述组合物包括:食用菌β-葡聚糖5份、桑多安1.5份、醣净6份、普洱茶晶1.5份、灵芝产品4份。
本发明以“构效、组效和量效”的方式,将食药用菌活性成分针对血脂异常人群进行靶向功能配方,通过个性化配方,精准化调理研究得到所述组合物,能够有效改善总胆固醇、甘油三酯、低密度脂蛋白胆固醇异常,且组方原料获取容易,可长期服用。
本发明所述食用菌β-葡聚糖来源于红托竹荪,更优选为来源于红托竹荪菌托。本发明所述红托竹荪β-葡聚糖与已批准的新食品原料β-1,3-葡聚糖的化学结构不完全相同,所述红托竹荪β-葡聚糖Smith降解产物中含有甘油、赤藓醇、阿拉伯糖、甘露糖、葡萄糖;所述红托竹荪β-葡聚糖中含有1-3糖苷键、1-2,3糖苷键、1-3,4糖苷键、1-3,6糖苷键和/或1-2,3,4糖苷键。本发明所述红托竹荪β-葡聚糖可常规购买或提取获得。
本发明所述红托竹荪β-葡聚糖具有较好的肝损伤修复效果。
本发明所述红托竹荪β-葡聚糖可以有效促进组合物血脂调理功效,与其他原料组分协同增效,在临床中靶向性调理总胆固醇、甘油三酯、低密度脂蛋白胆固醇异常指标。
本发明所述灵芝产品选自灵芝孢子油或灵芝孢子粉。
本发明所述桑多安、醣净、普洱茶晶、灵芝产品可常规购买获得或采用常规制备方法自制,所述桑多安、醣净、普洱茶晶、灵芝产品均为符合食品要求的产品。本发明所述各组分来源较广,容易获得,能有效带动相应产品的发展。
本发明还提供了上述组合物的制备方法,包括如下步骤:将各原料按所述配比依次混合得到混合物。
本发明所述组合物可直接服用,所述服用方式可选为每日早上服用1次,每次15~20g,持续服用60天;本发明所述组合物也可长期服用。
本发明还提供了上述组合物在制备调理血脂异常产品中的应用,所述产品包括食品、保健品或药品。
下面将结合本发明中的实施例,对本发明中的技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
下述实施例中,如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本发明所述具体实施例中,红托竹荪β-葡聚糖采用常规制备方法提取自红托竹荪菌托,新食品原料的β-葡聚糖、桑多安、醣净、普洱茶晶、灵芝孢子油、灵芝孢子粉、茶褐素、7天肠享均购自市场。
实施例1
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖4g、桑多安1g、醣净5g、普洱茶晶1g、灵芝孢子油3g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
实施例2
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖6g、桑多安2g、醣净7g、普洱茶晶2g、灵芝孢子油5g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
实施例3
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖5g、桑多安1.5g、醣净6g、普洱茶晶1.5g、灵芝孢子油4g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
实施例4
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖5g、桑多安1.5g、醣净6g、普洱茶晶1.5g、灵芝孢子粉4g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
对比例1
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖5g、桑多安1.5g、茶褐素2g、7天肠享20g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
对比例2
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖5g、桑多安1.5g、7天肠享20g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
对比例3
一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,所述组合物为:红托竹荪β-葡聚糖5g、茶褐素2g、醣净6g、普洱茶晶1.5g、灵芝孢子油4g。在常温负压洁净环境将各原料按所述配比依次混合得到混合物,即为所述组合物。
实施例5
本实施例对实施例1~4中的红托竹荪β-葡聚糖进行检测,各项实验结果均委托江南大学进行检测得到:
1、对红托竹荪β-葡聚糖的Smith降解产物进行检测:
Smith降解产物的GC色谱图见图1,图1中a为标准品GC色谱图,b为红托竹荪β-葡聚糖Smith降解产物GC色谱图;图中1为乙二醇;2为甘油;3为赤藓醇;4为鼠李糖;5为阿拉伯糖;6为木糖;7为甘露糖;8为葡萄糖;9为半乳糖。由图1可知,红托竹荪β-葡聚糖Smith降解产物中含有甘油、赤藓醇、阿拉伯糖、甘露糖、葡萄糖,可推测出中红托竹荪β-葡聚糖还含有1-3、1-2,3、1-3,4、1-3,6或1-2,3,4等糖苷键,具有三维螺旋结构。
2、红托竹荪和新食品原料的β-葡聚糖氧化反应实验:
氧化反应实验结果见图2,由图2可知,53h后在223nm处的吸光度值基本保持不变,表明氧化反应完全,证明红托竹荪β-葡聚糖存在有1-或1-6、1-2或1-4等糖苷键。
3、采用核磁共振分析红托竹荪β-葡聚糖结构:
红托竹荪β-葡聚糖核磁共振分析结果见图3,新食品原料的β-葡聚糖核磁共振分析结果见图4。图3~4表明红托竹荪β-葡聚糖含有α-糖苷键和β-糖苷键,存在吡喃型构型;新食品原料的β-葡聚糖存在吡喃型构型。
4、采用刚果红试验分析红托竹荪β-葡聚糖结构:
刚果红试验结果见图5。由图5可知,红托竹荪β-葡聚糖可以与刚果红形成复合物,产生红移,具有三维螺旋结构;而新食品原料的β-葡聚糖不与刚果红形成复合物,不产生红移,不具有三维螺旋结构。
实施例6
本实施例对实施例1~4中的红托竹荪β-葡聚糖进行酒精性肝损伤大鼠毒理实验:
将体重为160~180g的雄性SD大鼠在屏障系统中适应性喂养一周,随机分为空白对照组(NC组)、模型对照组(MC组)、阳性对照组(200mg/kg联苯双酯,PC组)、红托竹荪β-葡聚糖低剂量组(100mg/kg,LDRP组)、红托竹荪β-葡聚糖中剂量组(200mg/kg,MDRP组)、红托竹荪β-葡聚糖高剂量组(400mg/kg,HDRP组),每组10只。
实验期间,动物自由摄取饲料、饮水,阳性对照组和红托竹荪β-葡聚糖组分别按10ml/kg BW灌胃联苯双酯和不同浓度的红托竹荪β-葡聚糖,空白组和模型组灌胃等体积的蒸馏水。4h后,模型组、阳性对照组和红托竹荪β-葡聚糖干预组按12ml/kg BW灌胃60%酒精,空白组灌胃等体积的蒸馏水,连续灌胃28d(Tang et al.2017;Yang et al.2020)。动物每周称量2次,按体重调整灌胃量。在末次给药后,禁食不禁水16h,按照CO2吸入法处死动物,腹主动脉取血,离心后得到上层血清。立即解剖大鼠,用冰生理盐水冲洗肝脏,滤纸拭干后将肝左叶浸入10%中性缓冲福尔马林组织固定液中,剩余肝组织液氮冷冻后,置于-80℃保存。测定血生化指标、肝脏生化指标、肝脏病理学指标。
大鼠初始体重和终体重见表1。红托竹荪β-葡聚糖对酒精性肝损伤大鼠血清AST、ALT、TG的影响见图6,对酒精性肝损伤大鼠肝脏SOD、GSH、MDA的影响见图7,对酒精性肝损伤大鼠肝脏TNF-α和IL-6的影响见图8,图6~8中,不同的字母表示各组之间差异显著(P<0.05);酒精性肝损伤大鼠的肝脏组织形态学观察(400×)见图9,图9中,标尺=25μm。
表1红托竹荪β-葡聚糖对酒精性肝损伤大鼠体重的影响(n=10)
注:不同的字母表示各组之间差异显著(P<0.05)
由图6~9可知,与MC组相比,红托竹荪β-葡聚糖各剂量组血清AST、ALT、TG水平显著降低(P<0.05),肝脏SOD和GSH水平显著上升(P<0.05),MDA、TNF-α、IL-6含量显著下降(P<0.05),肝脏细胞变性和坏死等病理现象明显改善。表明红托竹荪β-葡聚糖具有一定的体外抗氧化能力,并且能缓解酒精所致的大鼠肝脏损伤,其缓解作用与抗氧化能力增强、炎症因子表达水平降低有关。
实施例7
本实施例开展基于血脂异常人群的临床试验:
试验纳入20~65岁血脂异常患者23名,随机分为对照组5名和干预组18名。实施干预前,分别对干预组和对照组对象实施基本情况问卷调查、身体测量和生化检查,包括血常规、肝功能4项、肾功能3项、血脂4项;干预结束后,分别对干预组和对照组对象实施身体测量和生化检查,包括血常规、肝功能4项、肾功能3项、血脂4项。
干预组1:5人,服用对比例1的组方产品
干预组2:5人,服用对比例2的组方产品
干预组3:2人,服用对比例3的组方产品
干预组4:6人,服用实施例3的组方产品
干预组对象每天早上口服1次,各干预组服用量相同(均为18g),持续服用60天。
通过分析试验结果发现,患者干预总胆固醇指标效果如下:
表2干预组总胆固醇指标效果
在干预二个月的18位血脂异常患者中,有14人总胆固醇指标超标。虽然干预后14人全部总胆固醇指标得到了改善,有效率为100%,总胆固醇均值由7mmol/L降到5.9mmol/L,总胆固醇均值降低了15.71%。其中干预组4中患者的总胆固醇改善效果较其他干预组更佳。
通过分析试验结果发现,患者干预甘油三酯指标效果如下:
表3干预组甘油三酯指标效果
在干预二个月的18位血脂异常患者中,有15人甘油三酯指标超标,干预后10人甘油三酯指标得到了改善,有效率为66.67%,甘油三酯均值由3.74mmol/L降到2.69mmol/L,甘油三酯均值降低了28.07%。其中干预组4中患者的有效率达到100%,干预组4中患者的甘油三酯指标改善效果较其他干预组更佳。
通过分析试验结果发现,患者干预低密度脂蛋白胆固醇指标效果如下:
表4干预组低密度脂蛋白胆固醇指标效果
在干预二个月的18位血脂异常患者中,有9人低密度脂蛋白胆固醇指标超标,干预后9人全部低密度脂蛋白胆固醇指标得到了改善,有效率为100%;低密度脂蛋白胆固醇均值由5.26mmol/L降到3.81mmol/L,低密度脂蛋白胆固醇均值降低了27.57%。其中干预组4中患者的低密度脂蛋白胆固醇指标改善效果较其他干预组更佳。
通过试验,2个月产品干预组表现都明显,有14人总胆固醇指标超标,干预后14人全部总胆固醇指标得到了改善,有效率为100%;有15人甘油三酯指标超标,干预后10人甘油三酯指标得到了改善,有效率为66.67%;有9人低密度脂蛋白胆固醇(也称为“坏胆固醇”)指标超标,干预后9人全部低密度脂蛋白胆固醇指标得到了改善,有效率为100%。其中干预组4中患者的三项指标改善效果均较其他干预组更佳。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种食用菌β-葡聚糖辅助靶向调理血脂的组合物,其特征在于,按质量份数计,所述组合物包括:食用菌β-葡聚糖4~6份、桑多安1~2份、醣净5~7份、普洱茶晶1~2份、灵芝产品3~5份。
2.根据权利要求1所述的组合物,其特征在于,按质量份数计,所述组合物包括:食用菌β-葡聚糖5份、桑多安1.5份、醣净6份、普洱茶晶1.5份、灵芝产品4份。
3.根据权利要求1所述的组合物,其特征在于,所述食用菌β-葡聚糖来源于红托竹荪。
4.根据权利要求3所述的组合物,其特征在于,所述红托竹荪β-葡聚糖Smith降解产物中含有甘油、赤藓醇、阿拉伯糖、甘露糖、葡萄糖。
5.根据权利要求3所述的组合物,其特征在于,所述红托竹荪β-葡聚糖中含有1-3糖苷键、1-2,3糖苷键、1-3,4糖苷键、1-3,6糖苷键和/或1-2,3,4糖苷键。
6.根据权利要求1所述的组合物,其特征在于,所述灵芝产品选自灵芝孢子油或灵芝孢子粉。
7.权利要求1~6任意一项所述的组合物的制备方法,其特征在于,包括如下步骤:将各原料按所述配比依次混合得到混合物。
8.权利要求1~6任意一项所述的组合物在制备调理血脂异常产品中的应用。
9.根据权利要求8所述的应用,其特征在于,所述产品包括食品、保健品或药品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310770263.XA CN116918972A (zh) | 2023-06-28 | 2023-06-28 | 一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310770263.XA CN116918972A (zh) | 2023-06-28 | 2023-06-28 | 一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116918972A true CN116918972A (zh) | 2023-10-24 |
Family
ID=88385470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310770263.XA Pending CN116918972A (zh) | 2023-06-28 | 2023-06-28 | 一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116918972A (zh) |
-
2023
- 2023-06-28 CN CN202310770263.XA patent/CN116918972A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guimarães et al. | Eggplant (Solanum melongena) infusion has a modest and transitory effect on hypercholesterolemic subjects | |
Mizuno | Medicinal properties and clinical effects of culinary-medicinal mushroom Agaricus blazei Murrill (Agaricomycetideae) | |
JP7069490B2 (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び/又は刺激におけるその使用 | |
CN101277710B (zh) | 减肥组成物 | |
US20200368301A1 (en) | Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same | |
Zhang et al. | Toxicology and immunology of Ganoderma lucidum polysaccharides in Kunming mice and Wistar rats | |
JP5498698B2 (ja) | シロキクラゲ雑多糖またはその抽出物の新用途 | |
Sokoloff et al. | Effect of ascorbic acid on certain blood fat metabolism factors in animals and man | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
KR20190128087A (ko) | 소화 건강, 체중 조절, 면역 강화 및 건강 개선을 위한 다중섬유 프리바이오틱 제제 | |
KR101349136B1 (ko) | 곤충 글라이코사미노글리칸을 유효성분으로 포함하는 지방간 또는 고지혈증 예방 또는 치료용 조성물 | |
EP2098240B1 (en) | Agent for promoting healing of living body | |
Lamiaa et al. | Hypolipidemic and antiatherogenic effects of dietary chitosan and wheat bran in high fat-high cholesterol fed rats | |
Zhang et al. | Characterization and hepatoprotections of Ganoderma lucidum polysaccharides against multiple organ dysfunction syndrome in mice | |
US5759543A (en) | Application of a cell culture of a fusarium fungus strain producer for medical uses | |
CN109620948A (zh) | 高尿酸/痛风的全自然细胞调理方法 | |
JP6883174B2 (ja) | 精製した(脱色した)アロエベラ葉乾燥液汁を使用した治療方法 | |
CN102106895A (zh) | 一种具有调节血脂功能的组合物 | |
CN116918972A (zh) | 一种食用菌β-葡聚糖辅助靶向调理血脂的组合物及其制备方法和应用 | |
JP2018070568A (ja) | 非アルコール性脂肪性肝疾患治療又は予防剤及び非アルコール性脂肪性肝疾患予防用食品 | |
Nurliyani et al. | Goat milk kefir supplemented with porang glucomannan improves lipid profile and haematological parameter in rat fed high fat and high fructose diet | |
WO2018084224A1 (ja) | 非アルコール性脂肪性肝疾患治療又は予防剤及び非アルコール性脂肪性肝疾患予防用食品 | |
Anionye et al. | Evaluation of the effects of super bitters on albino rats | |
US20050129789A1 (en) | Drugs including anticancer agents and immunopotentiators and health foods and drinks | |
KR101312025B1 (ko) | 소태나무 추출물의 제조방법 및 추출물의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |